STAAR Surgical Company Financial Results Announcement
STAAR Surgical Company (NASDAQ: STAA), recognized as a leading innovator in the field of ophthalmic surgery, has declared its upcoming financial results for the third quarter of the fiscal year. This announcement comes as the company prepares to share its achievements and future plans with stakeholders.
Important Date for Stakeholders
The financial results for the quarter that ended September 27, 2024, will be disclosed on Wednesday, October 30, 2024, after market hours. This timing allows investors and analysts to assimilate the results before the market opens the following day.
Webcast Event Details
STAAR will conduct a live webcast to discuss the third quarter financial outcomes and operational advancements. The webcast is scheduled for October 30 at 4:30 p.m. Eastern Time, which corresponds to 1:30 p.m. Pacific Time. Stakeholders who wish to join can access the webcast via a dedicated link that will be made available shortly before the event.
Replay of the Webcast
For those unable to attend the live session, an archived version of the webcast will also be available on the STAAR website by the evening of October 30, 2024, ensuring that every interested party has the opportunity to review the information discussed. The replay will remain accessible for at least 90 days.
About STAAR Surgical
With over 40 years of commitment to the advancement of ophthalmic surgery, STAAR Surgical focuses on the design, manufacturing, and distribution of innovative implantable lenses for vision correction. These lenses are pivotal in empowering patients with increased visual independence, significantly reducing or even eliminating their dependency on corrective eyewear, such as glasses or contact lenses.
Innovative Lens Technology
The flagship product line of STAAR includes the Implantable Collamer® Lens (ICL), particularly the EVO ICL™. This lens technology has revolutionized refractive surgery, allowing for a minimally invasive insertion process through a small incision, which greatly benefits both surgeons and patients. Throughout its journey, STAAR has successfully sold over 3 million ICLs across more than 75 countries, signifying its robust global presence and influence in optics.
Corporate Footprint
STAAR Surgical is headquartered in Lake Forest, California, and operates state-of-the-art manufacturing and packaging facilities located in Aliso Viejo, California, and Monrovia, California, as well as in Nidau, Switzerland. This strategic positioning not only facilitates the production of high-quality ophthalmic devices but also enables efficient distribution worldwide.
Frequently Asked Questions
What is the date of STAAR Surgical's financial results announcement?
STAAR Surgical is set to announce its financial results on October 30, 2024.
What time is the earnings webcast scheduled?
The earnings webcast will take place at 4:30 p.m. Eastern Time on October 30, 2024.
How can I access the replay of the webcast?
The replay of the webcast will be available on STAAR's website starting approximately at 8:00 p.m. Eastern Time on the same day of the announcement.
What innovations does STAAR Surgical offer?
STAAR Surgical specializes in developing ICLs, particularly the EVO ICL™, which has transformed refractive surgery.
Where are STAAR Surgical's manufacturing facilities located?
STAAR operates manufacturing facilities in California and Switzerland, ensuring quality production and global distribution.
